CPIXのチャート
CPIXの企業情報
| symbol | CPIx |
|---|---|
| 会社名 | Cumberland Pharmaceuticals Inc （カンバ―ランド・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 カンバーランド・ファーマシューティカルズ(Cumberland Pharmaceuticals Inc.)はブランド付き処方薬製品の取得、開発及び商品化に従事する医薬品専門会社である。同社は病院ケアと消化器市場向けの処方薬製品を開発・商業化する権利の取得を中心を行う。同社の製品ポートフォリオには、アセトアミノフェン中毒向けの治療薬「Acetadote」(アセチルシステイン)注射剤、疼痛・発熱向けの注射治療薬「Caldolor」(イブプロフェン)注射剤、下剤の処方薬の１種である経口液剤「Kristalose」(ラクツロース)、並びに肝腎症候群(HRS)を患っている患者の治療のための注射剤｢Hepatoren｣(イフェトロバン)が含まれる。平成23年12月31日現在、｢Hepatoren｣は第II相臨床開発段階における。平成23年11月、同社は｢Kristalose｣ブランドと関連する残る権利を取得した。平成23年12月期決算期において、同社は｢Hepatoren｣ブランド名で開発する後期段階の製品候補の権利を取得した。 カンバ―ランド・ファ―マシュ―ティカルズは米国の医薬品会社。処方箋薬の買収、開発、商業化を行う。主に救急薬と胃腸薬に重点を置く。主な製品はアセトアミノフェン中毒治療用注射剤｢アセタド―テ｣、急性疼痛・発熱治療用静脈内投与イブプロフェン｢カルドロ―ル｣など。 Cumberland Emerging Technologies, Inc.(www.cet-fund.com)is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies. |
| 本社所在地 | 2525 West End Avenue Suite 950 Nashville TN 37203 USA |
| 代表者氏名 | A. J. Kazimi A.J.カジミ |
| 代表者役職名 | Chairman of the Board Principal Executive Officer |
| 電話番号 | +1 615-255-0068 |
| 設立年月日 | 36161 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2009年 |
| 従業員数 | 84人 |
| url | www.cumberlandpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cpix |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -2.33567 |
| 終値（lastsale） | 5.8 |
| 時価総額（marketcap） | 90295090.2 |
| 時価総額 | 時価総額（百万ドル） 89.20532 |
| 売上高 | 売上高（百万ドル） 41.59758 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 50.49531 |
| 当期純利益 | 当期純利益（百万ドル） -4.84351 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cumberland Pharmaceuticals Inc. revenues increased 2% to $18.8M. Net loss before extraordinary items decreased 50% to $3.2M. Revenues reflect Caldolor increase of 22% to $6.5M Vaprisol increase of 85% to $1.8M Kristalose increase of 15% to $2.1M. Lower net loss reflects Selling and Marketing decrease of 2% to $9.7M (expense) Interest Income increase of 90% to $232K (income). |
CPIXのテクニカル分析
CPIXのニュース
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS 2023/05/02 20:05:00 PR Newswire
NASHVILLE, Tenn., May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2023 financial results and provide a company update after the market closes on Tuesday, May 9, 2023. A…
Vasopressin Antagonists Market to Reach USD 2.7 Bn by 2031 | TMR Study 2023/03/31 14:33:00 Accesswire
WILMINGTON, DE / ACCESSWIRE / March 31, 2023 / Transparency Market Research Inc. - The global vasopressin antagonists market stood at USD 1.7 Bn in 2022 and the global market is projected to reach USD 2.7 Bn by 2031. The global industry is anticipated to expand at a CAGR of 4.9% between 2023 and 2031. Hyponatremia is a common electrolyte disorder that affects millions of people worldwide. The rising prevalence of hyponatremia is expected to drive the demand for vasopressin antagonists, as they are the primary treatment option for this condition. Request for a Sample PDF Report with Insights, Charts, Tables, and Figures at https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85509 Market Snapshot: Report Coverage Details Market Revenue USD 1.7 Bn in 2022 Estimated Value USD 2.7 Bn by 2031 Growth Rate 4.9% Forecast Period 2023-2031 No. of Pages 183 Pages Market Segmentation By Drug Type, Application and Distribution Channel Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, South America Companies Covered Otsuka, Cumberland Pharmaceuticals, Mayo Clinic, and Hopital du Sacre-Coeur de Montreal The market value of the vasopressin antagonists is also increasing due to the growing incidence of heart failure.
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2022 Earnings Call Transcript 2023/03/08 03:47:02 Seeking Alpha
Cumberland Pharmaceuticals Inc. (NASDAQ:NASDAQ:CPIX) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ETCompany ParticipantsMolly Aggas - Account Supervisor, Dalton AgencyA.J.
Cumberland: Q4 Earnings Snapshot 2023/03/07 21:55:20 WTOP
NASHVILLE, Tenn. (AP) — NASHVILLE, Tenn. (AP) — Cumberland Pharmaceuticals Inc. (CPIX) on Tuesday reported a loss of $2.4 million…
Cumberland Pharmaceuticals GAAP EPS of -$0.17, revenue of $9.12M 2023/03/07 21:25:41 Seeking Alpha
Cumberland Pharmaceuticals press release (NASDAQ:CPIX): FY GAAP EPS of -$0.17.Revenue of $9.12M (+9.9% Y/Y).
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS 2022/11/01 20:05:00 PR Newswire
NASHVILLE, Tenn., Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financial results and provide a company update after the market closes on Tuesday, Nov. 8, 2022. A…
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q2 2022 Results - Earnings Call Transcript 2022/08/13 18:07:06 Seeking Alpha
Cumberland Pharmaceuticals Inc. (NASDAQ:NASDAQ:CPIX) Q2 2022 Results Conference Call August 9, 2022 04:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J.
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS 2022/08/02 20:05:00 PR Newswire
NASHVILLE, Tenn., Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug. 9, 2022….
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q1 2022 Results - Earnings Call Transcript 2022/05/14 21:42:06 Seeking Alpha
Cumberland Pharmaceuticals Inc. (NASDAQ:NASDAQ:CPIX) Q1 2022 Results Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency…
Cumberland Pharmaceuticals Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:CPIX) 2022/05/13 14:06:01 Seeking Alpha
The following slide deck was published by Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q2 2022 Results - Earnings Call Transcript 2022/08/13 18:07:06 Seeking Alpha
Cumberland Pharmaceuticals Inc. (NASDAQ:NASDAQ:CPIX) Q2 2022 Results Conference Call August 9, 2022 04:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J.
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS 2022/08/02 20:05:00 PR Newswire
NASHVILLE, Tenn., Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug. 9, 2022….
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q1 2022 Results - Earnings Call Transcript 2022/05/14 21:42:06 Seeking Alpha
Cumberland Pharmaceuticals Inc. (NASDAQ:NASDAQ:CPIX) Q1 2022 Results Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency…